News | March 17, 2026
BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
